story of the week
Nivolumab Plus Cabozantinib Improves Outcomes in Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab Plus Cabozantinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
N. Engl. J. Med 2021 Mar 04;384(9)829-841, TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, VM Oyervides Juárez, JJ Hsieh, U Basso, AY Shah, C Suárez, A Hamzaj, JC Goh, C Barrios, M Richardet, C Porta, R Kowalyszyn, JP Feregrino, J Żołnierek, D Pook, ER Kessler, Y Tomita, R Mizuno, J Bedke, J Zhang, MA Maurer, B Simsek, F Ejzykowicz, GM Schwab, AB Apolo, RJ Motzer, CheckMate 9ER InvestigatorsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.